Jul 13 2010
The first multiSENSE clinical trial began today with the admission of the first patient by a Texas M.D., Paul Coffeen who belongs to Austin Heart in Austin. The site’s Principal Investigator is Jeffrey Whitehill, M.D., Medical Chair and Electrophysiology Department.
Boston Scientific Corporation, which has announced the start of the trail, has decided to use the data from the trial to create a clinical alarm, which would produce a warning signal to identify heart failure.
The trial is meant to assess the several physiologic sensors used in the COGNIS cardiac resynchronization therapy defibrillators (CRT-Ds) from Boston Scientific. CRT-D’s sensors together with Boston Scientific’s LATITUDE® Patient Management System would help in vigilantly observing the patient away from the hospital setting and give an alarm if there is deterioration in the patient’s heart condition.
According to John Boehmer, Principal Investigator of the MultiSENSE trial and the M.D., Medical Director of Penn State Hershey Medical Center, doctors make use of a number of diagnostic tests to analyze the condition of the patient and advancement of a complex disease like heart failure. Hospitalization due to heart failure could be avoided and practitioners could take clinical action earlier by using devices in which multi-sensors are implanted. The multiple data points in them have the power to predict the patient’s condition.
M.D. and Chief Medical Officer, CRM, for Boston Scientific’s Cardiology, Rhythm and Vascular Group, Kenneth Stein, declared that the MultiSENSE trial was an important move to handle the requirements of patients having heart failure and also that the multi-sensor in the CRT-D’s would monitor the same information and symptoms a doctor tracks to judge the patient’s heart condition.
Heart failure, which is a fast-growing cardiovascular disorder, is a disease which incapacitates a patient’s life in terms of quality and also reduces the patient’s life expectancy, as the heart becomes weak and slowly stops pumping blood effectively. Every year more than one million people are diagnosed to have this disease and nearly 22 million people all over the world suffer from this disease currently.
Source link: http://www.bostonscientific.com